{"disease":{"id":"solid-tumor-kras-mutation","name":"solid tumor kras mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04185883","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":610,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06435455","title":"GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Suzhou Genhouse Bio Co., Ltd.","has_results":false},{"nct_id":"NCT06659341","title":"A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06270082","title":"Study of IK-595 in RAS- or RAF-altered Advanced Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":75,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT04111458","title":"A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT03965845","title":"A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false},{"nct_id":"NCT06056024","title":"A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT07468071","title":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07122882","title":"Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04965818","title":"Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT04973163","title":"A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04742556","title":"A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04380753","title":"AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04835714","title":"A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}